ArticleJournal of translational medicine2026
The MAPK/ATF3/ASNS axis drives amino acid metabolic reprogramming to promote NSCLC survival under glucose deprivation.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundGlucose deprivation is a prevalent stressor within the tumor microenvironment. Nonetheless, the fundamental mechanism through which non-small cell lung cancer (NSCLC) cells orchestrate survival and progression through specific metabolic hubs under such conditions remains poorly understood.
methodsThis study utilized integrated multiomics analyses, encompassing transcriptomics and metabolomics, to identify pivotal targets. Functional validation was performed via in vitro assays, including CCK-8, colony formation, Transwell, and EdU assays, as well as in vivo models, such as subcutaneous xenografts and tail-vein lung metastasis models. The function and mechanism of the MAPK/ATF3/ASNS signaling axis were comprehensively investigated using gene knockdown/overexpression techniques, Western blotting, immunohistochemistry, and metabolomic analysis.
resultsCombined transcriptomic and metabolomic analyses revealed that glucose deprivation markedly upregulates ASNS expression in NSCLC cells, correlating with unfavorable patient outcomes. Functionally, both in vitro and in vivo experiments confirmed that ASNS significantly promotes the malignant behaviors of NSCLC cells under glucose-deprived conditions. Metabolomic analysis revealed that ASNS supports tumor cell survival during energetic stress by maintaining a dynamic balance of multiple amino acids. Mechanistically, glucose deprivation activates the MAPK signaling pathway, leading to the upregulation of the transcription factor ATF3, which binds directly to the ASNS promoter and transcriptionally activates its expression, thereby promoting malignant progression in NSCLC. Finally, the combined targeting of glucose metabolism using 2-DG, along with ASNS inhibition, demonstrated additive antitumor efficacy in vivo.
conclusionThe results of this study revealed that, under glucose deprivation stress, the MAPK/ATF3/ASNS axis functions as a critical signaling-metabolic hub, promoting NSCLC progression by driving amino acid metabolic reprogramming. Targeting this axis offers a novel strategy for intervening in tumor metabolic adaptation and developing innovative combination therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.